Within the Institut Pasteur (http://www.pasteur.fr), the « institut Carnot Pasteur Maladies Infectieuses’s » initiative is to promote ambitious academic-industrial partnerships with biotechnology and healthcare industries. Through a better understanding of the fundamental mechanisms of host/pathogen interactions, Pasteur MI wishes to foster the development of innovative products in collaboration with industrial partners in 3 areas: therapeutic, diagnostic and vaccine.
- An identity built on a prestigious history
- Independence due to the status of the “Institut Pasteur” (non-for-profit private foundation) that strengthens its uniqueness, its flexibility and its capacity to mobilize expertise
- A comprehensive infrastructure supporting research and public health, including technological platforms, located on a single campus
- Proven track record of close collaborations with health industry
- Innovative technology transfer mechanisms leading to the creation of start-up companies or to commercialization, exemplifying an ambitious strategy to support all major bio-industry sectors
- Institut Pasteur is the National Reference Center For E. Coli And Shigella, Salmonella, Meningococcus, Listeria, Pertussis And Other Bordetella, Anaerobic Bacteria And Botulism
A multidisciplinary research
Pasteur MI strives to combine a unique know-how with multidisciplinary scientific approaches to offer its industrial partners relevant answers to major economic and public health issues.
- Mechanisms of bacterial, viral, fungal and parasitic pathogenesis
- Genetics and predisposition to infections
- Microbiota and human health
- Integrative biology
- Clinical and epidemiological studies
- New antimicrobial strategies
An internationally recognized actor
- Pasteur MI collaborates with the major international actors to advance life science research
- Existence of a unique international network of 32 “Instituts Pasteur “ located on each of the five continents, enriching scientific exchanges and offering a deep knowledge of the local fields
The Institut Pasteur MI’s scientific strategy focuses on:
- developing new topics for biomedical research,
- enhancing multidisciplinarity,
- and improving the transfer of scientific discoveries to applications.
The goal of our investigations is to understand basic mechanisms of host (in particular human) cells / pathogen interaction, to eventually develop tools to diagnose known or emerging pathologies, and to perform the clinical validation of vaccines and therapeutic treatments. Our research aims at providing an answer to today’s society expectations in public health problems, whether in developed countries (in particular AIDS, emergent or re-emergent diseases and resistance to antibiotic treatments) or in developing countries (in particular diseases of parasitic origin like malaria).
Basic research interests:
- Strategies for treatment of AIDS and cancers of infectious origin (various approaches are under way and some of them have reached the stage of clinical trials)
- Study of emergent diseases, in particular of viral origin, by contributing to the identification of pathogenic agents causing emergent pathologies or already known pathologies caused by unknown pathogenic agents, and by integrating environmental clues to identify the threat which medical authorities must face (lifespan of the virus or bacterium, drug resistance,…). Promising technologies are under development in partnership with industry partners, such as new micro-arrays generation, making it possible to explore in a single run the entire known viral world or, in the long term, to quickly identify a new virus in humans
- Study of resistance mechanisms to antibiotics and, more generally, mechanisms of adaptation of the pathogenic agents to their environment and study of virulence factors
- Fight against parasitic diseases (malaria, leishmaniosis, toxoplasmosis,…) which affect a significant number of persons in the world, mainly in developing countries. Important industrial partnerships were recently initiated and should extend in the next years, in particular to foster the development of new vaccines.
Example of pathogens we are working on:
- Viral Hantavirus, Influenza, neurovirus, hepatitis, poliomyelitis, yellow fever, dengue, SRAS, haemorrhagic fevers, AIDS, dengue
- ParasiticTrypanosoma, leishmaniasis, amibiasis, Chagas disease, Malaria…
- BacterialTuberculosis, enteric diseases, shigellosis, salmonellosis, plague, listeriosis, whooping cough, meningitis, anthrax, staphylococcus and streptococcus, resistance to antibiotics, legionellosis, spirochetes, leptospirosis
- Fungal Cryptococcosis, candidiasis, aspergillosis
Cutting-edge technological platforms
- Genopole: high throughput sequencing
- Proteopole: (labelled IBISA in 2008) protein production and purification, antibody engineering, mass spectrometry, crystallography
- Imagopole (labelled IBISA and certified ISO9001) dynamic imaging, ultra-structural microscopy, flow cytometry, the center for human immunology
- Zoopole: the mouse genetics engineering center, the central animal house facility, the center for the production and infection of anopheles (ISO9001 certification)
- Clinical investigation and access to biological resources
Partners in basic research
The collaborations extend well beyond France to meet global challenges and to be competitive in some highly dynamic areas of research.
Institut Pasteur researchers collaborate in large-scale European programs and maintain favored links with universities worldwide.
In parallel to its fundamental research activity, Institut Pasteur conducts applied research together with industrial partners. Common know-how and skills are shared in order to develop new products and services that can benefit to patients.
Several partnerships are ongoing with the industry, see examples in our Portfolio.
These programs leverage both our clinical and our non-clinical expertise to set-up collaborative research with our partners, ranging from fundamental, to clinical, translational and applied research in various domains.
Institut Pasteur is sharing its expertises and its technological platforms (see Core Facilities) via the consortium GLOBAL CARE Initiative.
Several partnerships are ongoing with the industry: Bio-Rad, Sanofi-Pasteur, Sanofi-Adventis, Biomérieux, Danone, L’Oréal, GlaxoSmithKline, Genticel, Pasteur-Cerba...